• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孟鲁司特儿科制剂的性能评价:第一部分——与年龄相关的体外条件。

Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.

机构信息

Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.

UCB Pharma S.A., Product Development, B-1420, Braine l'Alleud, Belgium.

出版信息

AAPS J. 2022 Jan 10;24(1):26. doi: 10.1208/s12248-021-00661-2.

DOI:10.1208/s12248-021-00661-2
PMID:35013835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8817206/
Abstract

This study aimed to explore the potential of biopharmaceutics in vitro tools to predict drug product performance in the pediatric population. Biorelevant dissolution set-ups were used to predict how age and medicine administration practices affect the in vitro dissolution of oral formulations of a poorly water-soluble compound, montelukast. Biorelevant age-appropriate dissolution studies of Singulair (granules and chewable tablets) were conducted with the µDISS profiler™, USP 4 apparatus, USP 2 apparatus, and mini-paddle apparatus. Biorelevant simulating fluids representative of adult and pediatric conditions were used in the dissolution studies. The biorelevant dissolution conditions were appropriately selected (i.e. volumes, transit times, etc.) to mimic the gastrointestinal conditions of each of the subpopulations tested. Partial least squares regression (PLS-R) was performed to understand the impact of in vitro variables on the dissolution of montelukast. Montelukast dissolution was significantly affected by the in vitro hydrodynamics used to perform the dissolution tests (µDISS profiler™: positive effect); choice of simulation of gastric (negative effect) and/or intestinal conditions (positive effect) of the gastrointestinal tract; and simulation of prandial state (fasted state: negative effect, fed state: positive effect). Age-related biorelevant dissolution of Singulair granules predicted the in vivo effect of the co-administration of the formulation with applesauce and formula in infants. This study demonstrates that age-appropriate biorelevant dissolution testing can be a valuable tool for the assessment of drug performance in the pediatric population.

摘要

本研究旨在探讨生物药剂学体外工具在预测儿科人群药物产品性能方面的潜力。使用生物相关溶解装置来预测年龄和用药实践如何影响一种水溶性差的化合物孟鲁司特的口服制剂的体外溶解。使用 µDISS profiler™、USP4 装置、USP2 装置和迷你桨板装置对 Singulair(颗粒剂和咀嚼片)进行了生物相关的适合年龄的溶解研究。在溶解研究中使用了代表成人和儿科条件的生物相关模拟液。生物相关的溶解条件经过适当选择(即体积、传输时间等),以模拟每个测试亚群的胃肠道条件。偏最小二乘回归(PLS-R)用于理解体外变量对孟鲁司特溶解的影响。孟鲁司特的溶解受到用于进行溶解测试的体外流体动力学的显著影响(µDISS profiler™:正效应);胃模拟选择(负面效应)和/或肠道条件模拟(正面效应)的选择;以及模拟进食状态(禁食状态:负面效应,进食状态:正面效应)。Singulair 颗粒剂的年龄相关生物相关溶解预测了该制剂与苹果酱和配方同时给药在婴儿体内的效果。本研究表明,适合年龄的生物相关溶解测试可以成为评估儿科人群药物性能的有价值工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/5282dadd981f/12248_2021_661_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/994dc80aab8f/12248_2021_661_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/794cfbddd10e/12248_2021_661_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/1f088a1c3168/12248_2021_661_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/1883e57a4d35/12248_2021_661_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/eb0006b41bc7/12248_2021_661_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/bb20948a035e/12248_2021_661_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/5282dadd981f/12248_2021_661_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/994dc80aab8f/12248_2021_661_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/794cfbddd10e/12248_2021_661_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/1f088a1c3168/12248_2021_661_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/1883e57a4d35/12248_2021_661_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/eb0006b41bc7/12248_2021_661_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/bb20948a035e/12248_2021_661_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a95/8817206/5282dadd981f/12248_2021_661_Fig7_HTML.jpg

相似文献

1
Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.孟鲁司特儿科制剂的性能评价:第一部分——与年龄相关的体外条件。
AAPS J. 2022 Jan 10;24(1):26. doi: 10.1208/s12248-021-00661-2.
2
Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.孟鲁司特儿科制剂的性能评估:第二部分-基于 PBPK 的建模方法。
AAPS J. 2022 Jan 10;24(1):27. doi: 10.1208/s12248-021-00662-1.
3
In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.婴儿服用饮料和软食时给予的孟鲁司特钠制剂的体内预测溶出度测试。
AAPS PharmSciTech. 2020 Oct 13;21(7):282. doi: 10.1208/s12249-020-01825-7.
4
Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.食品和饮料管理车辆对儿科配方性能的影响 第 2 部分:孟鲁司特钠和美沙拉嗪配方的溶解。
AAPS PharmSciTech. 2020 Oct 15;21(7):287. doi: 10.1208/s12249-020-01815-9.
5
Preparation and In Vitro Evaluation of Montelukast Sodium-Loaded 3D Printed Orodispersible Films for the Treatment of Asthma.孟鲁司特钠载 3D 打印口腔速溶膜的制备及体外评价用于哮喘治疗。
AAPS PharmSciTech. 2024 Sep 17;25(7):218. doi: 10.1208/s12249-024-02938-z.
6
Montelukast microsuspension with hypromellose for improved stability and oral absorption.孟鲁司特微悬浮液与羟丙甲纤维素,以提高稳定性和口服吸收。
Int J Biol Macromol. 2021 Jul 31;183:1732-1742. doi: 10.1016/j.ijbiomac.2021.05.151. Epub 2021 May 27.
7
Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.利用生物制药工具预测儿科患者的配方性能,并模拟硝苯地平和劳拉西泮的临床相关给药方案。
Br J Clin Pharmacol. 2019 Aug;85(8):1728-1739. doi: 10.1111/bcp.13956. Epub 2019 Jun 18.
8
Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.共处理水对含 N-乙酰半胱氨酸口服制剂体内性能的影响:采用动态开放流动通过测试装置的体外方法。
Mol Pharm. 2017 Dec 4;14(12):4272-4280. doi: 10.1021/acs.molpharmaceut.7b00763. Epub 2017 Nov 3.
9
In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.用于评估美沙拉嗪缓释产品以预测制剂和进餐对药物释放影响的体外生物相关模型。
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):39-50. doi: 10.1016/j.ejpb.2015.09.002. Epub 2015 Sep 21.
10
Simulation of in vitro dissolution behavior using DDDPlus™.使用DDDPlus™模拟体外溶出行为。
AAPS PharmSciTech. 2015 Feb;16(1):217-21. doi: 10.1208/s12249-014-0241-5. Epub 2014 Nov 20.

本文引用的文献

1
Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.食品和饮料管理车辆对儿科配方性能的影响 第 2 部分:孟鲁司特钠和美沙拉嗪配方的溶解。
AAPS PharmSciTech. 2020 Oct 15;21(7):287. doi: 10.1208/s12249-020-01815-9.
2
In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.婴儿服用饮料和软食时给予的孟鲁司特钠制剂的体内预测溶出度测试。
AAPS PharmSciTech. 2020 Oct 13;21(7):282. doi: 10.1208/s12249-020-01825-7.
3
A Biopredictive In Vitro Approach for Assessing Compatibility of a Novel Pediatric Hydrocortisone Drug Product within Common Pediatric Dosing Vehicles.
一种用于评估新型儿科氢化可的松药物产品在常见儿科给药载体中相容性的生物预测体外方法。
Pharm Res. 2020 Sep 24;37(10):203. doi: 10.1007/s11095-020-02912-x.
4
Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1-Effects on Solubility of Poorly Soluble Drugs.食品和饮料管理车辆对儿科配方性能的影响:第 1 部分-对难溶性药物溶解度的影响。
AAPS PharmSciTech. 2020 Jun 26;21(5):177. doi: 10.1208/s12249-020-01722-z.
5
Co-administration of Paediatric Medicines with Food and Drinks in the Context of Their Physicochemical Properties-a Global Perspective on Practices and Recommendations.儿科药物在其理化性质方面与食物和饮料共同给药-全球范围内的实践和建议。
AAPS J. 2020 Mar 4;22(2):54. doi: 10.1208/s12248-020-0432-9.
6
Magnetic Resonance Imaging Quantification of Gastrointestinal Liquid Volumes and Distribution in the Gastrointestinal Tract of Children.磁共振成像定量评估儿童胃肠道液体容量和分布。
Mol Pharm. 2019 Sep 3;16(9):3896-3903. doi: 10.1021/acs.molpharmaceut.9b00510. Epub 2019 Aug 15.
7
Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.利用生物制药工具预测儿科患者的配方性能,并模拟硝苯地平和劳拉西泮的临床相关给药方案。
Br J Clin Pharmacol. 2019 Aug;85(8):1728-1739. doi: 10.1111/bcp.13956. Epub 2019 Jun 18.
8
In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration.用于预测口服剂型体内性能的体外模型:通过 IMI OrBiTo 合作的伙伴关系取得的最新进展。
Eur J Pharm Biopharm. 2019 Mar;136:70-83. doi: 10.1016/j.ejpb.2018.12.010. Epub 2018 Dec 20.
9
Biorelevant in vitro assessment of dissolution and compatibility properties of a novel paediatric hydrocortisone drug product following exposure of the drug product to child-appropriate administration fluids.新型小儿氢化可的松药物制剂经儿童适用给药液暴露后的溶解和相容性的生物相关性体外评估。
Eur J Pharm Biopharm. 2018 Dec;133:277-284. doi: 10.1016/j.ejpb.2018.10.022. Epub 2018 Oct 29.
10
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.儿科生物制药考量因素,旨在评估口服药物产品 - PEARRL 综述。
J Pharm Pharmacol. 2019 Apr;71(4):603-642. doi: 10.1111/jphp.12955. Epub 2018 Jul 3.